Skip to main content
Premium Trial:

Request an Annual Quote

Abbott's MDx Sales Drop 2 Percent in Q2

NEW YORK (GenomeWeb) – Abbott today reported that its diagnostics sales jumped 5 percent year over year in the second quarter, but molecular diagnostics was a drag on the business, falling 2 percent.

The medical products giant reported total revenues of $5.55 billion for the quarter ended June 30, up 2 percent from $5.45 billion for Q2 2013.

Its diagnostics business recorded $1.19 billion in revenues for the quarter, up around 5 percent from $1.14 billion in Q2 2013. Its core laboratory diagnostics sales increased 6 percent year over year to $968 million, while its point-of-care diagnostics sales were up roughly 4 percent at $105 million.

Its molecular diagnostics sales, however, declined to $116 million from $119 million. Abbott said the decrease was due to the "timing of tenders in the infectious disease business in several emerging markets, which are expected to drive higher growth in the second half of 2014."

Abbott reported Q2 net earnings of $466 million, or $.30 per share, compared to $476 million, or $.30 per share, for Q2 2013. Its EPS from continuing operations increased to $.54 from $.46.

The firm raised its FY 2014 ongoing EPS guidance to a range of $2.19 to $2.29 from an earlier range of $2.16 to $2.26.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.